Case Report
Copyright ©The Author(s) 2021.
World J Clin Oncol. Apr 24, 2021; 12(4): 272-281
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.272
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Positron emission tomography/computed tomography scan shows pulmonary metastases and new development of right renal metastasis.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Diagnostic iodine-123 whole-body scan showing no tracer uptake in pulmonary and renal metastases. WBS: Whole-body scan.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Chest computed tomography shows pulmonary metastases progression from Hurthle cell thyroid cancer.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Positron emission tomography/computed tomography scan shows pulmonary metastases progression one year after treatment with sorafenib. PET: Positron emission tomography.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Positron emission tomography/computed tomography scan shows regression of pulmonary and renal metastases with lenvatinib.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Blood test trends during tyrosine kinase inhibitor treatment. A: Thyroglobulin; B: Hemoglobin; C: Platelet counts; D: Renal profile; E: Serum albumin levels during tyrosine kinase inhibitor therapy.